Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2000
06/27/2000US6080850 Nucleotide sequence of s gene with modified major enhancing epitopes; for vaccines without accelerated progression of disease
06/27/2000US6080757 Treatment of helicobacter (campylobacter) pylori infections; treatment and prevention of peptic ulcers, gastritis, dyspepsia, and gastric cancer
06/27/2000US6080756 Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin
06/27/2000US6080750 For prophylaxis and treatment of diseases caused by infection by rotavirus
06/27/2000US6080746 Methods and compositions for the prophylaxis and treatment of cytomegalovirus infections
06/27/2000US6080731 Dinucleoside-5', 5'-pyrophosphates administered to treat HIV
06/27/2000US6080729 Polypeptides and polynucleotides used to screen for antibacterial compounds
06/27/2000US6080717 Treatment of individual having a need to inhibit a polypeptide, comprising administering a bactericidal antagonist of the polypeptide
06/27/2000US6080427 Uncoated compressed tablets for oral administration by swallowing, chewing or drinking in water; containing microcrystalline cellulose, guar gum; polyvinylpyrrolidone, silica sol, dibasic calcium phoshate and mannitol
06/27/2000US6080408 Particles contain mutations to reduce gag-dependent rna-packaging of the gag gene product, eliminate reverse transcriptase, integrase activity and rnase h activity of the pol gene product through genetic manipulation; vaccines; aids
06/27/2000US6080400 Compositions for the prevention and treatment of verotoxin-induced disease
06/27/2000CA2076744C Viral agent associated with mystery swine disease
06/27/2000CA2058822C Antibacterial agents
06/22/2000WO2000036130A1 Foamy virus vectors for expressing foreign genes in mammals and the use thereof
06/22/2000WO2000036105A1 Prostacyclin-stimulating factor-2
06/22/2000WO2000035948A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000WO2000035945A1 Cyclic peptide antifungal agents having a sugar substituent
06/22/2000WO2000035944A1 Cyclic peptide antifungal agents
06/22/2000WO2000035943A1 Halovir, an antiviral marine natural product, and derivatives thereof
06/22/2000WO2000035934A1 Macrolide intermediates in the preparation of clarithromycin
06/22/2000WO2000035885A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
06/22/2000WO2000035882A1 1,2,3,4-tetrahydronaphthalenes and their pharmaceutical use
06/22/2000WO2000035871A1 Lactams
06/22/2000WO2000035862A1 Amido polybiguanides and the use thereof as antimicrobial agents
06/22/2000WO2000035482A2 Novel adjuvant for subunit or component vaccines
06/22/2000WO2000035481A2 Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
06/22/2000WO2000035480A2 Peptides useful in diagnosing and treating hiv-induced acquired immune deficiency disease
06/22/2000WO2000035479A1 Synthetic virus-like particles with heterologous epitopes
06/22/2000WO2000035478A1 Treatment of papillomavirus infections
06/22/2000WO2000035477A2 Multi-component vaccine comprising at least two antigens from haemophilus influenzae
06/22/2000WO2000035476A1 In ovo vaccination of 1 type marek's disease virus
06/22/2000WO2000035465A2 Oral administration of lactobacillus for the treatment and prevention of urogenital infection
06/22/2000WO2000035461A1 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
06/22/2000WO2000035460A2 Pharmaceutical formulations
06/22/2000WO2000035452A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
06/22/2000WO2000035442A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists
06/22/2000WO2000035440A1 N-formyl hydroxylamine derivatives as antibacterial agents
06/22/2000WO2000035430A2 Homer a new target of treating psychiatric disorders
06/22/2000WO2000035409A2 Hiv-i fusion inhibition compounds
06/22/2000WO2000035408A2 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
06/22/2000WO2000035289A1 Hydrogen peroxide disinfectant with increased activity
06/22/2000WO2000023955A8 Virus-like particles for the induction of autoantibodies
06/22/2000WO2000016632A3 Environmentally benign crop protection agents
06/22/2000WO2000015244A3 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
06/22/2000WO2000012048A3 Carbapenem antibacterial compositions and methods of treatment
06/22/2000WO2000010599A3 IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
06/22/2000WO2000009695A3 Drug targets in candida albicans
06/22/2000WO2000006736A3 Nucleic acids and proteins from group b streptococcus
06/22/2000WO1999066942A9 Compounds obtained from salvia species having antiviral activity
06/22/2000WO1999059615A9 Hybrid polypeptides with enhanced pharmacokinetic properties
06/22/2000CA2718376A1 Novel adjuvant for subunit or component vaccines
06/22/2000CA2440933A1 An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
06/22/2000CA2355890A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists
06/22/2000CA2355775A1 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
06/22/2000CA2355607A1 Anti-ccr5 antibody
06/22/2000CA2355363A1 Prostacyclin-stimulating factor-2
06/22/2000CA2355270A1 Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
06/22/2000CA2354451A1 Halovir, an antiviral marine natural product, and derivatives thereof
06/22/2000CA2354444A1 Synthetic virus-like particles with heterologous epitopes
06/22/2000CA2354323A1 Homer a new target of treating psychiatric disorders
06/22/2000CA2354056A1 Cyclic peptide antifungal agents
06/22/2000CA2354055A1 Cyclic peptide antifungal agents having a sugar substituent
06/22/2000CA2353924A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
06/22/2000CA2353866A1 Treatment of papillomavirus infections
06/22/2000CA2352570A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000CA2352079A1 Amido polybiguanides and the use thereof as antimicrobial agents
06/22/2000CA2347770A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
06/22/2000CA2320414A1 In ovo vaccination of type 1 marek's disease virus
06/22/2000CA2293023A1 Process for producing ucn-01
06/22/2000CA2290220A1 An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
06/22/2000CA2290219A1 Leptospira vaccine antigens for the prevention of leptospirosis
06/21/2000EP1010701A1 Process for the preparation of 3-cephem compounds
06/21/2000EP1010700A1 Process for the preparation of guanine under pressure
06/21/2000EP1010434A2 Inhibitor of Helicobacter pylori colonization
06/21/2000EP1009846A1 Alphavirus-derived vectors useful as vaccines providing protection against paramyxovirus infection
06/21/2000EP1009824A1 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-kappaB ACTIVATION
06/21/2000EP1009769A1 N-terminal modifications of rantes and methods of use
06/21/2000EP1009764A1 VACCINE COMPOSITIONS COMPRISING THE $i(HELICOBACTER PYLORI) FlgE POLYPEPTIDE
06/21/2000EP1009763A1 Synthetic hepatitis c genes
06/21/2000EP1009742A1 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors
06/21/2000EP1009737A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
06/21/2000EP1009732A2 1-amino-alkylcyclohexane nmda receptor antagonists
06/21/2000EP1009524A1 Improvements in or relating to capsules
06/21/2000EP1009447A1 Hydroxymethyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and method of making same
06/21/2000EP1009443A1 priA POLYPEPTIDES
06/21/2000EP1009430A1 Vaccines
06/21/2000EP1009428A1 Vaginal suppository vaccine for urogenital infections
06/21/2000EP1009426A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
06/21/2000EP1009415A1 INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR
06/21/2000EP1009405A1 Pyrrolidine and piperidine modulators of chemokine receptor activity
06/21/2000EP0825875B1 Therapeutic composition comprising an antigen or an in vivo generator for generating a compound comprising an amino acid sequence
06/21/2000DE19916224C1 Synthetic molecule for delivering active ingredient to cell, used e.g. to treat human immune deficiency virus infection, comprises the ingredient linked to VP2 or 3 peptide from polyoma virus
06/21/2000DE19858441A1 FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung FV vectors for expression of foreign genes in mammals and the use thereof
06/21/2000DE19857949A1 Verfahren zur Herstellung von Guanin unter Druck Process for the preparation of guanine under pressure
06/21/2000CN1257503A 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo (3,2-D] pyrimidine-4-ones
06/21/2000CN1257501A Process for preparing 6-0-monoesters of castanospermine
06/21/2000CN1257497A Sulfate salt of an HTV protease inhibitor having an improved oral absorption and bioavailability
06/21/2000CN1257486A Oxazolidinone antibacterial agents having a thiocarbonyl functionality
06/21/2000CN1257425A Gastroretentive controlled release microspheres for improved drug delivery
06/21/2000CN1256943A Ointment for promoting muscle growth
1 ... 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 ... 1798